RE:RE:RE:ASCO relevance
I have been around since 2000 and not going anywhere right now because of the pontential and possibilities. My problem is that the amount of time all of this is taking and rightly so for now but patents are getting close to expiring and even though extendable, my understanding that is only with an fda approval for the product although I might be wrong on this point and that is why the surrogate endpoints are so important as os for the MBC trial would as stated take a very long time unless for some reason the fda would possible grant an AA which would expidite things greatly and there still is the possiblitity of the Panc coming in very quickly as the OS could easily fall within reasonable peramiters so as to not have any strain on the possibility of patents expiring. Now ONC has also stated that they are always applying for new patents although have not seen anything new of late.
Preferences of course at this time by myself and most at this time seem to be a buyout so as to remove all dobut but hard to say where the mindset of ONC management and possible partners are.
Having said all of the that we can hope that there have been some major discussions with possible partners but none of us know for sure if this has happened and to what extent.
Matt seems confident that hopefully 2 phase 3 trials could be up and running this year at least what he has stated which would imply that talks are underway otherwise this would not be possible in such a short timeframe even with the hopeful results.
We will for sure have a much clearer picture after ASCO and I am sure that with the hopeful results that management will be more forthcoiming on what the near term future is for PELA.
We have had so many hopes from past trials which have never come to fruition and I believe that this is our best shot for the company and that for survival something positive needs to come out of all of this.
IMO only of course.